Chemotherapy News and Research

Latest Chemotherapy News and Research

RTOG study likely treatment option for brain tumor patients like Sen. Kennedy

A Radiation Therapy Oncology Group (RTOG) study which seeks to establish whether high-doses of the chemotherapy drug temozolomide after radiotherapy can improve outcome for patients with newly diagnosed malignant glioma is a possible consideration for Sen. Edward Kennedy (D-Mass.) and other patients with this type of brain tumor.

22 May 2008

Research shows protecting p53 from degradation also defends metastasis-promoter

Efforts to protect the tumor-suppressor p53 could just as easily shelter a mutant version of the protein, causing cancer cells to thrive and spread rather than die, according to research by scientists at The University of Texas M. D. Anderson Cancer Center reported in the current issue of the journal Genes and Development.

22 May 2008

Unique genetic signature alerts physicians to high-risk breast tumors

A unique genetic signature can alert physicians to high-risk breast tumors that are masquerading as low-risk tumors, according to research at Washington University School of Medicine in St. Louis and collaborating institutions. Although these tumors are apparently estrogen-receptor positive - meaning they should depend on estrogen to grow - they don't respond well to anti-estrogen therapy.

21 May 2008

Patriarch Edward Kennedy stricken with malignant brain tumour

The tragic history of the men in the legendary Kennedy family in the U.S. continues with the news this week that the Democratic patriarch Senator Edward Kennedy is suffering from a malignant brain tumour.

21 May 2008

Oncolytics Biotech announces issuance of 27th U.S. patent

Oncolytics Biotech Inc. today announced that it has been granted U.S. Patent 7,374,752 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders."

20 May 2008

Targeted therapy can improve outcomes for lung tumors

The first U.S. clinical trial using genetic screening to identify lung tumors likely to respond to targeted therapies supports the use of those drugs as first-line treatment rather than after standard chemotherapy has failed.

20 May 2008

Mapping of prostate cancer genes opens the door to new treatments

Genetic changes during the initiation and progression of prostate cancer have eluded scientists to date. Now for the first time researchers have identified a specific gene expression profile of prostate cancer stem cells, with important implications for future treatments.

19 May 2008

Spectrum Pharmaceuticals to present data on Ortataxel in breast cancer at major oncology meeting

Spectrum Pharmaceuticals, Inc., will present Phase 2 data on ortataxel at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 to June 3, 2008 at the McCormick Place Convention Center in Chicago, Illinois.

19 May 2008

Two California health insurers agree to reinstate coverage for 1,200 people whose policies were rescinded after incurring high medical bills

California health insurers Kaiser Permanente and Health Net on Thursday agreed to reinstate coverage to about 1,200 individuals whose policies were improperly rescinded, the San Francisco Chronicle reports.

19 May 2008

Asbestos-induced lung cancer patients do not appear to benefit from chemotherapy

Adding chemotherapy to established methods of symptom management does not appear to enhance the quality of life or survival of patients suffering from an asbestos-induced form of lung cancer called malignant plural mesothelioma (MPM). These are the results of MS01, a large UK and Australian study published in the Lancet, which set out to assess the potential benefits of combining active symptom control (ASC) with chemotherapy.

18 May 2008

New Wilmot Cancer Center offers expanded care, research for cures

The University of Rochester Medical Center (URMC) today celebrates the expansion of cancer care and research as it dedicates the new James P. Wilmot Cancer Center. The Center introduces leading-edge technology, greater access to multidisciplinary care, a new model for breast care, and more opportunities to receive tomorrow's therapies today.

15 May 2008

Arsenic-based agent shown to help eradicate leukemia-initiating cells

In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.

12 May 2008

New key mechanism in cell division discovered

Scientists at the IFOM-IEO Campus have revealed the function of a protein that is indispensable for passing on an accurate copy of the genome from mother to daughter cells. This study, published in Cell, opens up new avenues of research to reduce the toxicity of chemotherapy in the treatment of cancer.

8 May 2008

New deadly superbug Steno an ever-increasing threat

Scientists in the Britain say hospitals could be facing an increasing threat from yet another deadly bacterial infection with the potential to rapidly develop a resistance to drugs.

8 May 2008

Superbug genome sequenced

The genome of a newly-emerging superbug, commonly known as Steno, has just been sequenced. The results reveal an organism with a remarkable capacity for drug resistance. The research was carried out by scientists at the Wellcome Trust Sanger Institute near Cambridge and the University of Bristol.

6 May 2008

Biosimilar protein cooperation

A biosimilar protein that can be used to treat neutropenia (a side effect of cancer chemotherapy) is to be developed by Apotex Inc. of Canada in collaboration with Intas Biopharmaceuticals Limited (IBPL).

6 May 2008

Erythropoietin gene linked to severe diabetic eye, kidney diseases

Researchers at the John A. Moran Eye Center at the University of Utah and collaborative institutions have identified a gene called erythropoietin (EPO) that contributes to increased risk of severe diabetic eye and kidney diseases, called retinopathy and nephropathy.

6 May 2008

New drug added to chemo kills off residual breast cancer stem cells

New research says chemotherapy often fails to totally eliminate breast cancer because it does not knock out breast cancer stem cells.

30 Apr 2008

New cancer drug opportunities

An international study released this week in the prestigious journal Nature could revolutionise the way in which cancers are treated and potentially put an end to aggressive DNA damaging chemotherapies and radiotherapy treatments.

30 Apr 2008

Getting to the roots of breast cancer

The lesson learned in eradicating dandelions from your yard could apply in treating breast cancer as well, said researchers from Baylor College of Medicine in Houston in a report that appears online today in the Journal of the National Cancer Institute.

29 Apr 2008